Christopher Egan - 22 Nov 2021 Form 4 Insider Report for Definitive Healthcare Corp. (DH)

Role
Director
Signature
/s/ Christopher Egan
Issuer symbol
DH
Transactions as of
22 Nov 2021
Net transactions value
-$73,053,808
Form type
4
Filing time
24 Nov 2021, 16:01:12 UTC
Previous filing
21 Sep 2021
Next filing
13 Apr 2022

Key filing fact

Christopher Egan filed Form 4 for Definitive Healthcare Corp. (DH) on 24 Nov 2021.

Key facts

  • This page summarizes Christopher Egan's Form 4 filing for Definitive Healthcare Corp. (DH).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Filing timestamp: 24 Nov 2021, 16:01.

Change

  • Previous filing in this sequence was filed on 21 Sep 2021.
  • Current net transaction value: -$73,053,808.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Transactions Table

DH transaction

Class A Common Stock

Disposed to Issuer

Transaction value
$73,053,808
Shares
-2,102,873
Change %
-3.3%
Price
$34.74
Shares after
62,493,676
Date
22 Nov 2021
Ownership
See Notes
Footnotes
F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 See Exhibit 99.1 for text of footnote (1).
F2 See Exhibit 99.1 for text of footnote (2).
F3 See Exhibit 99.1 for text of footnote (3).
F4 See Exhibit 99.1 for text of footnote (4).

Remarks:

Exhibit 99.1 (Footnotes to Form 4) is incorporated by reference.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .